Rolph Timothy's Form 4 filing
Akero Therapeutics, Inc. (AKRO) · filed Sep 25, 2023
- Accession no.
- 0000950170-23-049764
- Filed
- Sep 25, 2023
- Trade date
- Sep 13, 2023
- Filing delay
- 12 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $26.7K. It was filed 12 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rolph TimothyCIK 0001779479 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2023 | Common Stock | SSaleDisposed | −531 | $50.34 | −$26,730.54 | 150,689 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.